These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34122826)

  • 1. Fc-binding antibody-recruiting molecules exploit endogenous antibodies for anti-tumor immune responses.
    Sasaki K; Harada M; Miyashita Y; Tagawa H; Kishimura A; Mori T; Katayama Y
    Chem Sci; 2020 Feb; 11(12):3208-3214. PubMed ID: 34122826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fc-Binding Antibody-Recruiting Molecules Targeting Prostate-Specific Membrane Antigen: Defucosylation of Antibody for Efficacy Improvement*.
    Sasaki K; Harada M; Yoshikawa T; Tagawa H; Harada Y; Yonemitsu Y; Ryujin T; Kishimura A; Mori T; Katayama Y
    Chembiochem; 2021 Feb; 22(3):496-500. PubMed ID: 32969164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological evaluation of a monocyclic Fc-binding antibody-recruiting molecule for cancer immunotherapy.
    Sasaki K; Muguruma K; Osawa R; Fukuda A; Taniguchi A; Kishimura A; Hayashi Y; Mori T; Katayama Y
    RSC Med Chem; 2021 Mar; 12(3):406-409. PubMed ID: 34046623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potentiation of tumor lysis by a bispecific antibody that binds to CA19-9 antigen and the Fc gamma receptor expressed by human large granular lymphocytes.
    de Palazzo IG; Gercel-Taylor C; Kitson J; Weiner LM
    Cancer Res; 1990 Nov; 50(22):7123-8. PubMed ID: 2146012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds.
    Liu H; Saxena A; Sidhu SS; Wu D
    Front Immunol; 2017; 8():38. PubMed ID: 28184223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conjugates of folate and anti-T-cell-receptor antibodies specifically target folate-receptor-positive tumor cells for lysis.
    Kranz DM; Patrick TA; Brigle KE; Spinella MJ; Roy EJ
    Proc Natl Acad Sci U S A; 1995 Sep; 92(20):9057-61. PubMed ID: 7568072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficiencies of bispecific F(ab'gamma)2 and chimeric mouse/human IgG antibodies in recruiting cellular effectors for cytotoxicity via Fc gamma receptors.
    Greenman J; Hogg N; Nikoletti S; Slade C; Stevenson G; Glennie M
    Cancer Immunol Immunother; 1992; 34(6):361-9. PubMed ID: 1532922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and characterization of novel dual Fc antibody with enhanced avidity for Fc receptors.
    Goulet DR; Zwolak A; Williams JA; Chiu ML; Atkins WM
    Proteins; 2020 May; 88(5):689-697. PubMed ID: 31702857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Towards a Rational Design of Antibody-Recruiting Molecules through a Computational Microscopy View of their Interactions with the Target Antibody.
    Uvyn A; Tonneaux C; Fossépré M; Ouvrier-Buffet A; De Geest BG; Surin M
    Chemistry; 2023 May; 29(30):e202300474. PubMed ID: 36862311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Production of target-specific effector cells using hetero-cross-linked aggregates containing anti-target cell and anti-Fc gamma receptor antibodies.
    Karpovsky B; Titus JA; Stephany DA; Segal DM
    J Exp Med; 1984 Dec; 160(6):1686-701. PubMed ID: 6239899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human K/natural killer cells targeted with hetero-cross-linked antibodies specifically lyse tumor cells in vitro and prevent tumor growth in vivo.
    Titus JA; Perez P; Kaubisch A; Garrido MA; Segal DM
    J Immunol; 1987 Nov; 139(9):3153-8. PubMed ID: 2959724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-domain antibody-based and linker-free bispecific antibodies targeting FcγRIII induce potent antitumor activity without recruiting regulatory T cells.
    Rozan C; Cornillon A; Pétiard C; Chartier M; Behar G; Boix C; Kerfelec B; Robert B; Pèlegrin A; Chames P; Teillaud JL; Baty D
    Mol Cancer Ther; 2013 Aug; 12(8):1481-91. PubMed ID: 23757164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future.
    Fournier P; Schirrmacher V
    BioDrugs; 2013 Feb; 27(1):35-53. PubMed ID: 23329400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity.
    Wang Y; Liu J; Pan H; Xing J; Wu X; Li Q; Wang Z
    J Vis Exp; 2018 Jul; (137):. PubMed ID: 30059039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bispecific antibodies targeting cancer cells.
    Peipp M; Valerius T
    Biochem Soc Trans; 2002 Aug; 30(4):507-11. PubMed ID: 12196124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study.
    Shock A; Burkly L; Wakefield I; Peters C; Garber E; Ferrant J; Taylor FR; Su L; Hsu YM; Hutto D; Amirkhosravi A; Meyer T; Francis J; Malcolm S; Robinson M; Brown D; Shaw S; Foulkes R; Lawson A; Harari O; Bourne T; Maloney A; Weir N
    Arthritis Res Ther; 2015 Sep; 17(1):234. PubMed ID: 26335795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
    MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial trial of bispecific antibody-mediated immunotherapy of CD15-bearing tumors: cytotoxicity of human tumor cells using a bispecific antibody comprised of anti-CD15 (MoAb PM81) and anti-CD64/Fc gamma RI (MoAb 32).
    Ball ED; Guyre PM; Mills L; Fisher J; Dinces NB; Fanger MW
    J Hematother; 1992; 1(1):85-94. PubMed ID: 1365020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A recombinant bispecific single-chain fragment variable specific for HLA class II and Fc alpha RI (CD89) recruits polymorphonuclear neutrophils for efficient lysis of malignant B lymphoid cells.
    Guettinger Y; Barbin K; Peipp M; Bruenke J; Dechant M; Horner H; Thierschmidt D; Valerius T; Repp R; Fey GH; Stockmeyer B
    J Immunol; 2010 Feb; 184(3):1210-7. PubMed ID: 20042573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding the role of cross-arm binding efficiency in the activity of monoclonal and multispecific therapeutic antibodies.
    Harms BD; Kearns JD; Iadevaia S; Lugovskoy AA
    Methods; 2014 Jan; 65(1):95-104. PubMed ID: 23872324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.